Rekah Pharmaceutical Industry Ltd. (TASE: REKA)
Health Care · Pharmaceuticals · IL
₪10.54
-1.13% today · -9.1% 1Y
Rekah Pharmaceutical Industry Ltd. (TASE: REKA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $40.25M and employs 390 people.
Over the last twelve months the share price has lost 9.1%, trading between 10.06 and 13.48.
Tweenvest scores Rekah Pharmaceutical Industry Ltd. across four factors: quality 50/100, value 55/100. Its strongest factor is value.
REKA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $40.25M
- Revenue (TTM)
- $96.33M
- P/E
- —
- EPS
- -1.62
- Dividend yield
- —
- Beta (5Y)
- 0.11
- 52-week high
- ₪13.48
- 52-week low
- ₪10.06
- Avg volume (3M)
- —
- Shares outstanding
- 11.41M
- Employees
- 390
- Next earnings
- —
About Rekah Pharmaceutical Industry Ltd.
Rekah Pharmaceutical Industry Ltd., established in 1941 and headquartered in Holon, Israel, specializes in the production, marketing, distribution, and sale of a broad spectrum of healthcare items across Israel. The company's offerings include both prescription and over-the-counter medicines, dermo-cosmetic products, vitamins, and nutritional supplements. Its extensive portfolio comprises approximately 280 distinct pharmaceutical drugs used in various medical sectors. These encompass steroid tablets, antibiotics (such as penicillin and cephalosporin), eye drops and ointments for allergies, infections, and dryness, baby products, and dermatological treatments.
- ISIN
- IL0010810096
- Founded
- 1947
- Listed since
- Aug 12, 2002
- Exchange
- The Tel-Aviv Stock Exchange
- Currency
- ILS
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.